Axel Hoos, M.D., Ph.D.
Dr. Axel Hoos is vice president, Oncology R&D at GlaxoSmithKline Pharmaceuticals (GSK), where he directs clinical and translational research on molecular mechanisms of cancer and tumor-host interactions for rational combination of therapies to optimize patient outcomes. Prior to his current role, Dr. Hoos was the medical lead in immunology/oncology at Bristol-Myers Squibb (BMS) where he developed the Yervoy (Ipilimumab; anti CTLA-4) monoclonal antibody in melanoma and other indications. Yervoy is approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Australian Therapeutic Goods Administration (TGA), and is the first therapy to extend survival in metastatic melanoma. Before BMS, Dr. Hoos was senior director of clinical development at Antigenics Inc., a biotechnology company, which develops therapies for cancer and infectious diseases.
Dr. Hoos also serves as co-director of the Cancer Immunotherapy Consortium (CIC) of the New York City-based Cancer Research Institute (CRI), an organization advancing the science and development of immune therapies against malignant disease. Further, he serves as a member of the Board of Trustees of the Albert B. Sabin Vaccine Institute in Washington D.C., which is focused on new vaccine development, vaccine advocacy, and the fight against neglected tropical diseases.
In these capacities, he focuses on developing novel therapies for life-threatening diseases with a special interest for innovative approaches to facilitate scientific exchange and improvement of the drug development process. Through his leadership, a new clinical development paradigm for cancer immunotherapy has been defined, geared to enable reproducible success for this emerging group of treatments.
Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ) both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich, Germany, and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.